Dark Forest Capital Management LP Invests $4.30 Million in Bruker Corporation $BRKR

Key Points

• Dark Forest Capital Management LP has invested approximately $4.30 million in Bruker Corporation, acquiring 102,917 shares during the first quarter.
• Bruker recently reported quarterly earnings of $0.32 EPS, missing estimates, and projected FY 2025 guidance of 1.950-2.050 EPS amid a revenue decline of 0.4% year-over-year.
• The company also announced a quarterly dividend of $0.05 per share, representing an annualized yield of 0.6%, with dividends payable on October 3rd.

Dark Forest Capital Management LP acquired a new position in Bruker Corporation (NASDAQ:BRKR - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 102,917 shares of the medical research company's stock, valued at approximately $4,296,000. Dark Forest Capital Management LP owned about 0.07% of Bruker as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. VeriStar Capital Management LP bought a new stake in shares of Bruker in the 1st quarter worth approximately $3,473,000. Focus Partners Advisor Solutions LLC bought a new stake in Bruker during the 1st quarter valued at $332,000. Royal Bank of Canada raised its holdings in Bruker by 8.3% during the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company's stock valued at $5,148,000 after buying an additional 9,501 shares during the last quarter. Caption Management LLC bought a new stake in Bruker during the 1st quarter valued at $835,000. Finally, Sculptor Capital LP raised its holdings in Bruker by 51.6% during the 1st quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company's stock valued at $108,459,000 after buying an additional 884,423 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Stock Down 1.0%

BRKR stock traded down $0.32 during trading on Monday, hitting $30.51. 1,063,739 shares of the stock traded hands, compared to its average volume of 2,643,617. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $72.94. The firm's 50 day moving average is $37.12 and its two-hundred day moving average is $39.51. The stock has a market cap of $4.63 billion, a price-to-earnings ratio of 58.67, a price-to-earnings-growth ratio of 3.84 and a beta of 1.22. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. During the same period last year, the company posted $0.52 earnings per share. The business's revenue for the quarter was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, sell-side analysts anticipate that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be paid a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.7%. Bruker's dividend payout ratio is currently 38.46%.

Analyst Ratings Changes

A number of research firms recently commented on BRKR. Citigroup lowered their price target on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, August 4th. Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the company a "hold" rating in a report on Tuesday, August 5th. Barclays reduced their price objective on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Monday, August 4th. Wells Fargo & Company reduced their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th. Finally, Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the company a "buy" rating in a research report on Monday, August 4th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.